Evidence map›Paper›PMID 31980905›Full record

Trial reportHuman genetics2020

A new mutational hotspot in the SKI gene in the context of MFS/TAA molecular diagnosis.

Pauline Arnaud, Caroline Racine, Nadine Hanna, Julien Thevenon, Jean-Luc Alessandri, Dominique Bonneau, Jill Clayton-Smith, Christine Coubes, Bruno Delobel, Sophie Dupuis-Girod and 8 more

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Human genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. The Molecular Genetics of Marfan Syndrome.International journal of medical sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 15 institutions in 3 countries.

Pauline ArnaudLaboratory for Vascular Translational Science, INSERM U1148, Centre Hospitalo-Universitaire Xavier Bichat, 75018, Paris, France.
Caroline RacineCentre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs de l'interrégion Est et FHU TRANSLAD, Hôpital d'Enfants, Centre Hospitalier Universitaire Dijon, 14, Rue Gaffarel, 21079, Dijon Cedex, France.
Nadine HannaLaboratory for Vascular Translational Science, INSERM U1148, Centre Hospitalo-Universitaire Xavier Bichat, 75018, Paris, France.
Julien ThevenonUnité de Génétique Clinique,Pôle Couple Enfant, CHU de Grenoble Site Nord-Hôpital Couple-Enfant, 38043, Grenoble, France.
Jean-Luc AlessandriService de Réanimation Néonatale, Pole Femme-Mère-Enfant, CH Felix Guyon, CHU de La Réunion, La Réunion, Saint-Denis, France.
Dominique BonneauDépartement de Biochimie et Génétique et Unité Mitovasc INSERM 1083, CNRS 6015, CHU Angers, 49933, Angers, France.
Jill Clayton-SmithManchester Centre For Genomic Medicine, St Mary's Hospital, Manchester and University Hospitals NHS Foundation Trust Manchester Academic Health Sciences Centre, Manchester, UK.
Christine CoubesCentre de Référence Anomalies du Développement et Syndromes Malformatifs Sud-Languedoc Roussillon, Centre Hospitalier Universitaire Montpellier, Montpellier, France.
Bruno DelobelCentre de Génétique Chromosomique, GHICL, Hôpital Saint Vincent de Paul, Lille, France.
Sophie Dupuis-GirodCentre de Compétences Syndrome de Marfan et Syndromes Apparentés, Hospices Civils de Lyon, Lyon, France.
Laurent GouyaCentre de Référence Syndrome de Marfan et Pathologies Apparentés, APHP, Hôpital Bichat, Paris, France.
Sylvie OdentCentre de Référence Anomalies du Développement et Syndromes Malformatifs de l'inter-région Ouest, Service de Génétique Clinique, Univ Rennes, CNRS, IGDR (Institut de Génétique et Développement de Rennes)-UMR 6290, Centre Hospitalier Universitaire Rennes, 35203, Rennes, France.
Virginie CarmignacINSERM, U1231, Génétique des Anomalies du Développement, 21079, Dijon, France.
Christel Thauvin-RobinetINSERM, U1231, Génétique des Anomalies du Développement, 21079, Dijon, France.
Carine Le GoffLaboratory for Vascular Translational Science, INSERM U1148, Centre Hospitalo-Universitaire Xavier Bichat, 75018, Paris, France.
Guillaume JondeauLaboratory for Vascular Translational Science, INSERM U1148, Centre Hospitalo-Universitaire Xavier Bichat, 75018, Paris, France.
Catherine BoileauLaboratory for Vascular Translational Science, INSERM U1148, Centre Hospitalo-Universitaire Xavier Bichat, 75018, Paris, France. catherine.boileau@aphp.fr.
Laurence FaivreCentre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs de l'interrégion Est et FHU TRANSLAD, Hôpital d'Enfants, Centre Hospitalier Universitaire Dijon, 14, Rue Gaffarel, 21079, Dijon Cedex, France. laurence.faivre@chu-dijon.fr.
Université Claude Bernard Lyon 1 · FRUniversité de Bourgogne · FRUniversité Paris Cité · FRAssistance Publique – Hôpitaux de Paris · FRCentre Hospitalier Universitaire de La Réunion · FRCentre National de la Recherche Scientifique · FRCHU Dijon Bourgogne · FRHôpital Bichat-Claude-Bernard · FRHôpital Couple Enfant · FRHôpital Lapeyronie · FRHôpital Saint-Vincent-de-Paul · FRHospices Civils de Lyon · FRInstitut de génétique et de développement de Rennes · FRUniversité Bourgogne Franche-Comté · FRUniversity of Manchester · GB

Funding

RENAL PATHOGENICITY OF ANTIDNA ANTIBODIESK08AR002015 · NIAMS · YESHIVA UNIVERSITY · PI PUTTERMAN, CHAIM · 1997 to 2001
$252k
Conseil régional de Bourgogne-Franche-Comté European Union through the PO FEDER-FSE Bourgogne 2014/2020 programs.Conseil régional de Bourgogne-Franche-Comté Plan d'Actions Régional pour l'Innovation (PARI 2015)
6 · The paper itself

Abstract

SKI pathogenic variations are associated with Shprintzen-Goldberg Syndrome (SGS), a rare systemic connective tissue disorder characterized by craniofacial, skeletal and cardiovascular features. So far, the clinical description, including intellectual disability, has been relatively homogeneous, and the known pathogenic variations were located in two different hotspots of the SKI gene. In the course of diagnosing Marfan syndrome and related disorders, we identified nine sporadic probands (aged 2-47 years) carrying three different likely pathogenic or pathogenic variants in the SKI gene affecting the same amino acid (Thr180). Seven of these molecular events were confirmed de novo. All probands displayed a milder morphological phenotype with a marfanoid habitus that did not initially lead to a clinical diagnosis of SGS. Only three of them had learning disorders, and none had intellectual disability. Six out of nine presented thoracic aortic aneurysm, which led to preventive surgery in the oldest case. This report extends the phenotypic spectrum of variants identified in the SKI gene. We describe a new mutational hotspot associated with a marfanoid syndrome with no intellectual disability. Cardiovascular involvement was confirmed in a significant number of cases, highlighting the importance of accurately diagnosing SGS and ensuring appropriate medical treatment and follow-up.

Indexed as

ArachnodactylyCraniosynostosesMarfan SyndromeMutationAdolescentAdultChildChild, PreschoolDNA-Binding ProteinsFemaleHumansMaleMiddle AgedPathology, MolecularProto-Oncogene ProteinsDNA-Binding ProteinsProto-Oncogene ProteinsSKI protein, human

Identifiers

PMID31980905
OpenAlexW3002448076

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.